2012-02-11 04:02:26 - New Pharmaceuticals market report from Global Markets Direct: "Community-Acquired Infections - Pipeline Review, H1 2012"

Community-Acquired Infections - Pipeline Review, H1 2012

Summary

Global Markets Direct's, 'Community-Acquired Infections - Pipeline Review, H1 2012', provides an overview of the Community-Acquired Infections therapeutic pipeline. This report provides information on the therapeutic development for Community-Acquired Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Community-Acquired Infections. 'Community-Acquired Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report

Details at
- www.fastmr.com/prod/330175_communityacquired_infections_pipeline ..


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Community-Acquired Infections.
* A review of the Community-Acquired Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Community-Acquired Infections pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Community-Acquired Infections.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Community-Acquired Infections pipeline depth and focus of Community-Acquired Infections therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Community-Acquired Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Community-Acquired Infections
Community-Acquired Infections Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Community-Acquired Infections Therapeutics - Products under Development by Companies
Companies Involved in Community-Acquired Infections Therapeutics Development
Rib-X Pharmaceuticals, Inc.
Warner Chilcott Limited
Optimer Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
Dongwha Pharm Co., Ltd.
Enanta Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals Inc.
Community-Acquired Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Omadacycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RX-3341 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RX-1741 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OP-1068 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DW-224 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EDP-420 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nemonoxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-Q2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-434 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Community-Acquired Infections Therapeutics - Drug Profile Updates
Community-Acquired Infections Therapeutics - Discontinued Products
Community-Acquired Infections Therapeutics - Dormant Products
Community-Acquired Infections - Product Development Milestones
Featured News & Press Releases
Sep 15, 2011: Cempra Announces Comparable Efficacy Of Oral Solithromycin Compared With Levofloxacin In Phase II Clinical Trial In Patients With Community-Acquired Bacterial Pneumonia
Jan 19, 2006: Enanta Pharmaceuticals Announces Initiation Of Phase II Studies in North America On First-In-Class Antibiotic EDP-420 for the Treatment of Community Acquired Pneumonia
Jun 26, 2001: AstraZeneca Submits sNDA for Merrem I.V for the treatment of Hospital Acquired Pneumonia (HAP) and Community Acquired Pneumonia (CAP)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Community-Acquired Infections, H1 2012
Products under Development for Community-Acquired Infections - Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Rib-X Pharmaceuticals, Inc., H1 2012
Warner Chilcott Limited, H1 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=330175&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.